UPDATE : Tuesday, October 15, 2019
Samsung, Genentech settle patent dispute on Herceptin biosimilar by Lee Han-soo 2019-07-05 11:47
Kolon confident to resume US trial on Invossa by Lee Hye-seon 2019-07-04 14:05
China OKs Alteogen’s Herceptin biosimilar for clinical trials by Lee Han-soo 2019-07-04 14:04
Regulator revokes Invossa license; Kolon CEO ‘to fight in court’ by Lee Hye-seon 2019-07-03 11:52
BNO BIO to invest $1 million in Israeli biotech venture by Jeong Sae-im 2019-06-28 16:10
Shareholders in shock over HLB’s phase-3 trial setback by Jeong Sae-im 2019-06-28 10:47
‘Food and drug ministry alone can’t handle Invossa debacle’ by Jeong Sae-im 2019-06-27 12:45
Oscotech wins exception policy for continued R&D for new drugs by Jeong Sae-im 2019-06-25 14:11
Despite regulator’s ruling delay, Kolon TissueGene likely to be reviewed for delisting by Jeong Sae-im 2019-06-20 14:20
294 shareholders file suit against Kolon TissueGene for damage compensation by Jeong Sae-im 2019-06-14 10:51
Celltrion unveils P3 trial results for rheumatoid biosimilar in Europe by Lee Han-soo 2019-06-13 16:10
Kolon TissueGene CEO resigns by Jeong Sae-im 2019-06-07 15:35
[ASCO 2019] ‘Ontruzant demonstrates equal quality to original drug’ by Lee Han-soo, KBR correspondent 2019-06-04 14:17
Kolon’s minority shareholders demand over ₩25 billion in damage by Jeong Sae-im 2019-06-03 14:53
Invossa inventor sold Kolon shares at highest value by Jeong Sae-im 2019-06-03 14:52
Until when will Kolon keep lying about Invossa? by Jeong Sae-im 2019-05-31 14:59
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug by Jeong Sae-im 2019-05-31 14:59
Announcement of Invossa license revocation was ‘procedural breach’: Kolon by Jeong Sae-im 2019-05-30 13:28
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy by Kim Yun-mi 2019-05-29 12:35
Invossa poses almost no safety threat: regulator by Lee Hye-seon 2019-05-28 16:02
Back to Top